Summary
In a randomized clinical trial, gemcitabine (GEM) was more effective than 5-fluorouracil (5-FU) in advanced pancreatic cancer patients. GEM and 5-FU have different mechanisms of action and their combination, from a theoretical point of view, could result in a higher activity. To test activity and feasibility of such a combination, a multi-institutional phase II study was initiated in November 1996 by the Italian Group for the study of Digestive Tract Cancer (GISCAD). Primary objectives of this study were to determine the activity in terms of response rate and clinical benefit, while the secondary objective was toxicity. According to the optimal two-stage phase II design, 54 patients were enrolled. Schedule was: GEM 1000 mg m–2 intravenous (i.v.), and 5-FU 600 mg m–2 bolus i.v. weekly for 3 weeks out of every 4. All the 54 patients were symptomatic (pain, weight loss, dyspepsia). A clinical benefit was obtained in 28 patients (51%) (95% confidence interval (CI) 38–64%). Two patients achieved a partial response and 34 a stable disease. Median survival for all the patients was 7 months. Side-effects were mild: no gastrointestinal or haematological grade 3–4 toxicity (WHO) were recorded. We observed only six episodes of grade 2 (WHO) leukopenia and seven episodes of thrombocytopenia. Although the non-randomized design of this study suggests caution in the interpretation of these data, in consideration of the low incidence of toxicity and the favourable results obtained in terms of clinical benefit, it may be worthwhile to test more active schedules of 5-FU (continuous infusion) in combination with gemcitabine.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ahlgren, J. D. (1996). Chemotherapy for pancreatic cancer. Cancer 78: 654–663.
Burris, III H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D. & Von Hoff, D. D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413.
Carmichael, J., Fink, U., Russel, R. C. G., Spittle, M. F., Harris, A. & Spiessl, G. (1995). Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101–105.
Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D. & Flombaum, C. D. (1994). Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest New Drug 12: 29–35.
DeCaprio, J. A., Mayer, R. J., Gonin, R. & Arbuck, S. G. (1991). Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 9: 2128–2133.
Grindey, G. B., Hertel, L. W. & Plunkett, W. (1990). Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycitidine (Gemcitabine). Cancer Invest 8: 313–318.
Heinemann, V., Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B. & Plunkett, W. (1991). Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′,2′-difluorodeoxycitidine. Mol Pharmacol 38: 567–572.
Kelly, D. M. & Benjamin, I. S. (1995). Pancreatic carcinoma. Ann Oncol 6: 19–28.
Lionetto, R., Pugliese, V., Bruzzi, P. & Rosso, R. (1995). No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 6: 882–887.
Miller, A. B., Hoodgstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Moore, M. (1996). Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 78: 633–638.
Parker, S. L., Tong, T., Bold, S. & Wingo, P. A. (1997). Cancer statistics, 1997. CA Cancer Clin 47: 5–27.
Popescu, R. A. & Cunningham, D. (1997). Chemotherapy for advanced pancreatic cancer. Some lights at the end of the tunnel? Ann Oncol 8: 415–416.
Rothenberg, M. L., Abbruzzese, J. L., Moore, M., Portenoy, R. K., Robertson, J. M. & Wanebo, H. J. (1996). A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78: 627–632.
Rothenberg, L. M., Moore, M. J., Cripps, M. C., Andersen, J. S., Portenoy, R. K., Burris, III H. A., Green, M. R., Tarassoff, P. G., Brown, T. D., Casper, E. S., Storniolo, A. M. & Von Hoff, D. D. (1996). A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann Oncol 7: 347–353.
Rougier, P., De Forni, M., Adenis, A., Ducreux, M., Djazouli, K., Adams, D., Bonneterre, J., Clouet, P., Blanc, C., Bayssas, M. & Armand, J. P. (1994). Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13: 200
Schnall, S. & Macdonald, J. S. (1996). Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220–228.
Scher, M. N., Kosierowski, R., Lusch, C., Alexander, R., Fox, S., Redei, I., Green, F., Raskay, B., Amfoh, K., Engstrom, P. F. & O’Dwyer, P. J. (1996). Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 13: 347–354.
Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1–10.
Taylor, I. (1993). Should further studies of chemotherapy be carried out in pancreatic cancer?. Eur J Cancer 29: 1076–1078.
Wagener, D. J. T., Verdonk, H. E. R., Dirix, L. Y., Catimel, G., Siegenthaler, P., Buitenhuis, M., Mathieu-Boué, A. & Verweij, J. (1995). Phase II trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trial group study. Ann Oncol 6: 129–132.
Whitehead, R. P., Jacobson, J., Brown, T. D., Taylor, S. A., Weiss, G. R. & Macdonald, J. S. (1997). Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group Study. J Clin Oncol 15: 2414–2419.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cascinu, S., Silva, R., Barni, S. et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 80, 1595–1598 (1999). https://doi.org/10.1038/sj.bjc.6690568
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690568
Keywords
This article is cited by
-
5-Fluorouracil Loaded Chitosan–PVA/Na+MMT Nanocomposite Films for Drug Release and Antimicrobial Activity
Nano-Micro Letters (2016)
-
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial
Cancer Chemotherapy and Pharmacology (2006)
-
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
British Journal of Cancer (2005)
-
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)
Clinical and Translational Oncology (2005)
-
A phase II irinotecan–cisplatin combination in advanced pancreatic cancer
British Journal of Cancer (2003)